Suppr超能文献

对即时检测 HIV-1 RNA 用于诊断和治疗的性能和临床实用性的系统评价。

Systematic review of the performance and clinical utility of point of care HIV-1 RNA testing for diagnosis and care.

机构信息

Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya.

International AIDS Vaccine Initiative (IAVI), Department of Medical Affairs, New York, New York, United States of America.

出版信息

PLoS One. 2019 Jun 27;14(6):e0218369. doi: 10.1371/journal.pone.0218369. eCollection 2019.

Abstract

BACKGROUND

Point of-care (POC) HIV-1 RNA tests which are accurate and easy to use with limited infrastructure are needed in resource-limited settings (RLS). We systematically reviewed evidence of POC test performance compared to laboratory-based HIV-1 RNA assays and the potential utility of these tests for diagnosis and care in RLS.

METHODS

Studies published up to July 2018 were identified by a search of PUBMED, EMBASE, Web of Science, CINAHL and Cochrane Central Register of Controlled Trials. Studies evaluating the use of POC HIV-1 RNA testing for early infant diagnosis (EID), acute HIV infection (AHI) diagnosis, or viral load monitoring (VL), compared to centralized testing, were included. Separate search strategies were used for each testing objective.

RESULTS

197 abstracts were screened and 34 full-text articles were assessed, of which 32 met inclusion criteria. Thirty studies evaluated performance and diagnostic accuracy of POC tests compared to standard reference tests. Two of the thirty and two additional studies with no comparative testing reported on clinical utility of POC results. Five different POC tests (Cepheid GeneXpert HIV-1 Quantitative and Qualitative assays, Alere q HIV-1/2 Detect, SAMBA, Liat HIV Quant and Aptima HIV-1 Quant) were used in 21 studies of VL, 11 of EID and 2 of AHI. POC tests were easy to use, had rapid turnaround times, and comparable accuracy and precision to reference technologies. Sensitivity and specificity were high for EID and AHI but lower for VL. For VL, lower sensitivity was reported for whole blood and dried blood spots compared to plasma samples. Reported error rates for Cepheid GeneXpert Qual (2.0%-5.0%), GeneXpert Quant (2.5%-17.0%) and Alere q HIV-1/2 Detect (3.1%-11.0%) were higher than in WHO prequalification reports. Most errors resolved with retesting; however, inadequate sample volumes often precluded repeat testing. Only two studies used POC results for clinical management, one for EID and another for VL. POC EID resulted in shorter time-to-result, rapid ART initiation, and better retention in care compared to centralised testing.

CONCLUSIONS

Performance of POC HIV-1 RNA tests is comparable to reference assays, and have potential to improve patient outcomes. Additional studies on implementation in limited-resources settings are needed.

摘要

背景

在资源有限的环境下,需要能够准确且易于使用的即时检测(POC)HIV-1 RNA 检测方法,以便有限的基础设施也能进行 HIV-1 RNA 检测。我们系统地综述了 POC 检测方法与实验室 HIV-1 RNA 检测方法相比的性能证据,以及这些检测方法在资源有限环境中的诊断和临床应用的潜力。

方法

通过对 PUBMED、EMBASE、Web of Science、CINAHL 和 Cochrane 中央对照试验注册中心进行检索,确定了截至 2018 年 7 月的研究。纳入了评估 POC HIV-1 RNA 检测在早期婴儿诊断(EID)、急性 HIV 感染(AHI)诊断或病毒载量监测(VL)方面的应用,并与集中检测进行比较的研究。每个检测目标都使用了单独的搜索策略。

结果

筛选了 197 篇摘要,评估了 34 篇全文文章,其中 32 篇符合纳入标准。30 项研究评估了 POC 检测与标准参考检测相比的性能和诊断准确性。30 项研究中有两项和另外两项没有比较性检测的研究报告了 POC 结果的临床应用。21 项 VL 研究、11 项 EID 研究和 2 项 AHI 研究使用了 5 种不同的 POC 检测方法(Cepheid GeneXpert HIV-1 定量和定性检测、Alere q HIV-1/2 Detect、Samba、Liat HIV Quant 和 Aptima HIV-1 Quant)。POC 检测易于使用,具有快速周转时间,与参考技术相比具有相似的准确性和精密度。EID 和 AHI 的敏感性和特异性较高,但 VL 较低。与血浆样本相比,全血和干血斑的 VL 检测敏感性较低。Cepheid GeneXpert Qual(2.0%-5.0%)、GeneXpert Quant(2.5%-17.0%)和 Alere q HIV-1/2 Detect(3.1%-11.0%)的报告错误率高于世界卫生组织预认证报告。大多数错误通过重新检测得到解决;然而,样本量不足通常妨碍了重复检测。只有两项研究使用了 POC 结果进行临床管理,一项用于 EID,另一项用于 VL。与集中检测相比,POC EID 可缩短结果时间、快速启动 ART 并改善护理保留率。

结论

POC HIV-1 RNA 检测的性能与参考检测方法相当,并且有可能改善患者的预后。需要在资源有限的环境中开展更多关于实施的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f03/6597060/4512a2258924/pone.0218369.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验